Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Clin Ther. 2020 Aug 12;42(9):1637–1648. doi: 10.1016/j.clinthera.2020.06.011

Table III.

Details on effective probiotic clinical trials.

Year Published Study Center Product Control Dose of probiotic Target Patient Age No. of Enrolled Patients Detailed Results Citation
2007 Australia Lactobacillus rhamnosus GG Placebo 1.0 × 109 CFU daily (in 100 g yogurt vehicle) VRE Adults 24 0/12 in treatment group remained VRE-positive vs 11/12 in control group at 3 weeks 32
2011 Poland L rhamnosus GG Placebo 3.0 × 109 CFU daily VRE Pediatric 61 12/32 in treatment group remained VRE-positive vs 22/29 in control group at 3 weeks 36
2014 China Multiple strains Placebo Bifidobacterium longum (2.5 × 106 CFU) Lactobacillus bulgaricus (2.5 × 105 CFU), Streptococcus thermophiles (2.5 × 105 CFU) twice daily ESBL enteric Preterm infants 257 27/93 in treatment group had detectable ESBL enteric colonization by 14 days vs 40/102 in control group for non-breastfeeding infants. No difference was observed in breastfed infants 39
2020 Turkey L rhamnosus GG SOC 1 × 109 CFU daily VRE Newborn 45 1/22 in treatment group remained VRE + vs 11/23 in the control group at 6 months 49

CFU = colony-forming units; ESBL = extended-spectrum beta-lactamase; MDR = multidrug-resistant; SOC = standard of care; VRE = vancomycin-resistant Enterococcus.